1. Home
  2. ENSC

ENSC

Ensysce Biosciences Inc.

Logo Ensysce Biosciences Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 2:32pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Founded: 2003 Country:
United States
United States
Employees: 8 City: LA JOLLA
Market Cap: 4.3M IPO Year: N/A
Target Price: $7.00 AVG Volume (30 days): 1.5M
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -4.69 EPS Growth: N/A
52 Week Low/High: $0.72 - $7.20 Next Earning Date: 05-13-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): 724.66%

Share on Social Networks: